Morgan Stanley’s private equity secondaries business and Hayfin have co-led a GP-led deal involving a drug company that was recently partially exited to KKR. The company, Immedica Pharma, was founded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results